RRM1 and RRM2 pharmacogenetics: Association with phenotypes in HapMap cell lines and acute myeloid leukemia patients

Pharmacogenomics

Volumn 14, Issue 12, 2013, Pages 1449-1466

  Cao, Xueyuan ^a   Mitra, Amit K ^b   Pounds, Stanley ^a   Crews, Kristine R ^a   Gandhi, Varsha ^c   Plunkett, William ^c   Dolan, M Eileen ^d   Hartford, Christine ^a   Raimondi, Susana ^a   Campana, Dario ^a,e   Downing, James ^a   Rubnitz, Jeffrey E ^a   Ribeiro, Raul C ^a   Lamba, Jatinder K ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

cytarabine; HapMap; leukemia; nucleoside analogs; pharmacogenomics; ribonucleotide reductase

Indexed keywords

1 BETA DEXTRO ARABINOFURANOSYL CYTIDINE TRIPHOSPHATE; CLADRIBINE; CYTARABINE; CYTIDINE TRIPHOSPHATE; DAUNORUBICIN; ETOPOSIDE; GENOMIC DNA; MESSENGER RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESPONSE; GENE; GENE EXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE MAP; HUMAN; HUMAN CELL; HUMAN TISSUE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHARMACOGENETICS; PHENOTYPE; PROMOTER REGION; RECURRENCE RISK; RRM1 GENE; RRM2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

CELL LINE, TUMOR; CLADRIBINE; CYTARABINE; GENETIC ASSOCIATION STUDIES; HAPMAP PROJECT; HUMANS; LEUKEMIA, MYELOID, ACUTE; LINKAGE DISEQUILIBRIUM; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; TUMOR SUPPRESSOR PROTEINS;

EID: 84883865174     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.131     Document Type: Article

References (37)

1. Liliemark JO, Plunkett W. Regulation of 1-b-d-arabinofuranosylcytosine 5́-triphosphate accumulation in human leukemia cells by deoxycytidine 5́-triphosphate. Cancer Res. 46(3), 1079-1083 (1986
2. Chabner BA, Hande KR, Drake JC. Ara-C Metabolism: Implications for drug resistance and drug interactions. Bull. Cancer 66(1), 89-92 (1979
3. Chiba P, Tihan T, Szekeres T et al. Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo. Leukemia 4(11), 761-765 (1990
4. Tattersall MH, Ganeshaguru K, Hoffbrand AV. Mechanisms of resistance of human acute leukaemia cells to cytosine arabinoside. Br. J. Haematol. 27(1), 39-46 (1974
5. Meuth M. The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells. Exp. Cell Res. 181(2), 305-316 (1989
6. Lotfi K, Juliusson G, Albertioni F. Pharmacological basis for cladribine resistance. Leuk. Lymphoma 44(10), 1705-1712 (2003
7. Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony- stimulating factor during therapy of acute myelogenous leukemia. Clin. Cancer Res. 1(2), 169-178 (1995
8. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol. 11(1), 116-124 (1993
9. Gandhi V, Estey E, Keating MJ, Plunkett W. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk. Lymphoma 10(Suppl.), S109-S114 (1993
10. Gandhi V, Estey E, Du M, Keating MJ, Plunkett W. Minimum dose of fludarabine for the maximal modulation of 1-b-d-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin. Cancer Res. 3(9), 1539-1545 (1997
11. Gautam A, Bepler G. Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. Cancer Res. 66(13), 6497-6502 (2006
12. Cros E, Jordheim L, Dumontet C, Galmarini CM. Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk. Lymphoma 45(6), 1123-1132 (2004
13. Shao J, Zhou B, Chu B, Yen Y. Ribonucleotide reductase inhibitors and future drug design. Curr. Cancer Drug Targets 6(5), 409-431 (2006
14. Nakahira S, Nakamori S, Tsujie M et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int. J. Cancer 120(6), 1355-1363 (2007
15. Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/ cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 10(4), 1318-1325 (2004
16. Bergman AM, Eijk PP, Ruiz van Haperen VW et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res. 65(20), 9510-9516 (2005
17. Hartford CM, Duan S, Delaney SM et al. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113(10), 2145-2153 (2009
18. Mitra AK, Crews KR, Pounds S et al. Genetic variants in cytosolic 5́-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J. Pharmacol. Exp. Ther. 339(1), 9-23 (2011
19. Rubnitz JE, Crews KR, Pounds S et al. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: Results of the St Jude AML97 trial. Leukemia 23(8), 1410-1416 (2009
20. Rubnitz JE, Inaba H, Dahl G et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: Results of the AML02 multicentre trial. Lancet Oncol. 11(6), 543-552 (2010
21. Crews KR, Gandhi V, Srivastava DK et al. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J. Clin. Oncol. 20(20), 4217-4224 (2002
22. Holleman A, Cheok MH, Den Boer ML et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 351(6), 533-542 (2004
23. Lamba JK, Crews KR, Pounds SB et al. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics 12(3), 327-339 (2011
24. Wolfinger RD. Heterogeneous variance-covariance structures for repeated measures. J. Agric. Biol. Environ. Sci. 1(2), 205-230 (1996
25. Jung SH, Owzar K, George SL. A multiple testing procedure to associate gene expression levels with survival. Stat. Med. 24(20), 3077-3088 (2005
26. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann. Stat. 16, 14 (1988
27. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 14 (1999
28. Erculj N, Kovac V, Hmeljak J, Franko A, Dodic-Fikfak M, Dolzan V. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. Pharmacogenet. Genomics 22(1), 58-68 (2012
29. Kwon WS, Rha SY, Choi YH et al. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet. Genomics 16(6), 429-438 (2006
30. Bepler G, Zheng Z, Gautam A et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 47(2), 183-192 (2005
31. Dong S, Guo AL, Chen ZH et al. RRM1 single nucleotide polymorphism -37C->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. J. Hematol. Oncol. 3, 10 (2010
32. Feng JF, Wu JZ, Hu SN et al. Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer. Lung Cancer 66(3), 344-349 (2009
33. Isla D, Sarries C, Rosell R et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15(8), 1194-1203 (2004
34. Kim SO, Jeong JY, Kim MR et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin. Cancer Res. 14(10), 3083-3088 (2008
35. Rodriguez J, Boni V, Hernandez A et al. Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy. Eur. J. Cancer 47(6), 839-847 (2011
36. Liu X, Lai L, Wang X et al. Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer. Cancer Res. 71(9), 3202-3213 (2011
37. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM. The sounds of silence: SDynonymous mutations affect function. Pharmacogenomics 8(6), 527-532 (2007